Shun Matsuura

Dr. Shun Matsuura

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
SMShun Matsuura
Shun Matsuura
KSKoji Shibazaki
Koji Shibazaki
RUReiko Uchida
Reiko Uchida
YIYukiko Imai
Yukiko Imai
TMTakuya Mukoyama
Takuya Mukoyama
HMHiroshi Morita
Hiroshi Morita
Aims/Introduction: Diabetes and sarcopenia have a two‐way relationship with each other with advanced age. Additionally, malnutrition is correlated with a higher risk of sarcopenia in elderly patients. This study evaluated the association between sarcopenia and geriatric nutritional risk index (GNRI) in elderly patients with type 2 diabetes mellitus.Materials and Methods: Patients with type 2 diabetes mellitus aged ≥60 years were recruited from June 2018 to August 2020. This study analyzed 234 patients, who completed a physical performance test required for the diagnosis of sarcopenia. To investigate the effect of GNRI on sarcopenia, logistic regression analyses was used.Results: Patients with sarcopenia were significantly older with a lower body mass index (BMI) and GNRI compared with normal patients. The GNRI showed a positive correlation with the skeletal muscle index (SMI) and handgrip strength (SMI: R = 0.486, P < 0.001 for male; R = 0.589, P < 0.001 for female, handgrip strength: R = 0.470, P < 0.001 for male, R = 0.364, P < 0.001 for female). In the multivariate logistic regression model, a higher GNRI was associated with a lower risk of sarcopenia in older men and women with diabetes (adjusted odds ratio [OR], 0.892; 95% confidence interval [CI], 0.839–0.948 for male; adjusted OR, 0.928; 95% CI, 0.876–0.982 for female). One year of diabetes treatment improved the GNRI in the sarcopenia group with type 2 diabetes mellitus.Conclusions: A low GNRI was associated with an increased risk of sarcopenia in elderly patients with type 2 diabetes mellitus. Treatment with glucose‐lowering drugs improved the GNRI in the sarcopenia group.

25 August 2021 in Nutrition and Cancer
Verified
Journal Article
Closed access
SMShun Matsuura
Shun Matsuura
KMKeisuke Morikawa
Keisuke Morikawa
YIYutaro Ito
Yutaro Ito
TKTsutomu Kubota
Tsutomu Kubota
KIKoshiro Ichijo
Koshiro Ichijo
NKNaoki Koshimizu
Naoki Koshimizu
We aimed to assess the prognostic and predictive significance of pretreatment Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) measurements on advanced non-small cell lung cancer (NSCLC) patients treated with first-line therapy. Patients with advanced NSCLC treated between February 2014 and August 2020 were retrospectively analyzed. The optimal cutoff points for GNRI and PNI were measured with receiver operating characteristic (ROC) curve analysis according to overall survival (OS). The predictive factors for progression-free survival (PFS) and OS were evaluated with univariate and multivariate analyses via the Cox hazards regression. A total of 160 patients were included in the study. Significant differences between the low and high-GNRI or PNI groups were found regarding ECOG-PS. The low-GNRI and low-PNI groups had significantly shorter PFS and OS than the high-GNRI and high-PNI groups. A multivariate analysis using a Cox regression model revealed that the high-GNRI group was an independent prognostic factor of OS and PFS, and the PNI group was an independent prognostic factor of OS. Pretreatment GNRI and PNI may therefore be a potential effective predictor of the survival of advanced NSCLC patients undergoing first-line treatment.

11 October 2025 in Respiratory Investigation
Verified
Journal Article
Closed access
SMShun Matsuura
Shun Matsuura

12 April 2023 in Annals of Medicine
Verified
Journal Article
Open access
SMShun Matsuura
Shun Matsuura
SSSayaka Serizawa
Sayaka Serizawa
RYRyoma Yamashita
Ryoma Yamashita
KMKeisuke Morikawa
Keisuke Morikawa
YIYutaro Ito
Yutaro Ito
TKTakashi Kosugi
Takashi Kosugi
Adjuvant durvalumab after chemoradiation has become the standard of care for patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before durvalumab for patients with st...

1 January 2017 in Internal Medicine
Verified
Journal Article
Open access
SMShun Matsuura
Shun Matsuura
YMYasutaka Mochizuka
Yasutaka Mochizuka
KOKyohei Oishi
Kyohei Oishi
KMKoichi Miyashita
Koichi Miyashita
HNHyogo Naoi
Hyogo Naoi
TSTakahumi Suda
Takahumi Suda
Sarcoidosis affects multiple organs and rarely has unusual manifestations. A 78-year-old woman was referred to our hospital for coughing symptoms. A chest computed tomography (CT) scan revealed bilateral diffuse miliary patterns and right pleural effusion. Bronchoscopy showed multiple nodules in the carina and the bronchus intermedius. A CT scan of her abdomen revealed hypovascular lesions involving the pancreatic head and body. A transbronchial lung biopsy, bronchial mucosal biopsy, and endoscopic ultrasound-guided fine-needle aspiration of the pancreatic mass demonstrated non-caseating granulomas. We diagnosed the patient with sarcoidosis. She received no treatment for sarcoidosis and has been followed up for one year, during which no pulmonary disease progression had been observed and the pancreatic masses partially regressed.

17 February 2018 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
EMEisuke Mochizuki
Eisuke Mochizuki
SMShun Matsuura
Shun Matsuura
KOKyohei Oishi
Kyohei Oishi
KMKoichi Miyashita
Koichi Miyashita
KIKoshiro Ichijyo
Koshiro Ichijyo
TSToshihiro Shirai
Toshihiro Shirai
There are few reports about the factor influencing the prognosis of high-grade neuroendocrine carcinoma. In this study, we evaluated surgical outcome of clinical stage I high-grade neuroendocrine carcinoma. Patients who underwent curative surgery for high-grade neuroendocrine tumors of the lung in clinical stage I were included in this study. We retrospectively analyzed 27 consecutive patients. The aim of this study was to clarify the clinical course of the disease after surgery and what factors influence the prognosis. Twenty-two patients have small cell carcinoma, and 5 patients have large cell neuroendocrine carcinoma. Patients who could undergo surgery within 60 days after the first visit (p < 0.01) and undergo lobectomy (p < 0.01) and whose pro-gastrin-releasing peptide ≦ 72 pg/ml (p = 0.04) performed good prognosis after surgery. In multivariate analysis, surgery within 60 days and operative procedure were independent factors associated with OS. Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung should be performed as early as possible, and better outcome can be obtained with lobectomy than partial resection.